• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:33:09 PM ET
    $ONVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ONVO alert in real time by email
    SC 13G/A 1 tm216840d29_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 5)*

     

     

    Organovo Holdings, Inc.

     

    (Name of Issuer)

     

     

    Common Stock

     

    (Title of Class of Securities)

     

     

    68620A104

     

    (CUSIP Number)

     

     

    December 31, 2020

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)

    ¨  Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 68620A104 13G Page 2 of 5 Pages 

     

    1. NAMES OF REPORTING PERSONS    
    ARK Investment Management LLC    
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP    
    (a)☐    
    (b)☐    
    3. SEC USE ONLY    
         
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware, United States    
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER    

    1,401,092

       
       
    6. SHARED VOTING POWER    
     3,528    
       
    7. SOLE DISPOSITIVE POWER    

    1,404,620

       
       
    8. SHARED DISPOSITIVE POWER    
    0    
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    

    1,404,620

       
       
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    
    ☐    
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    20.86%    
       
    12. TYPE OF REPORTING PERSON    
    IA    
       
               

     

     

     

     

    CUSIP No. 68620A104 13G Page 3 of 5 Pages 

     

    Item 1(a) Name of issuer:

     

    Organovo Holdings, Inc.

      

    Item 1(b) Address of issuer's principal executive offices:

     

    440 Stevens Avenue

    Solana Beach, CA 92075

     

    Item 2(a) Name of person filing:

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    3 East 28th Street, 7th Floor

    New York, NY 10016

     

    Item 2(c) Citizenship:

     

    Delaware, United States 

     

    Item 2(d) Title of class of securities:

     

    Common Stock

     

    Item 2(e) CUSIP No.:

     

    68620A104

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

    CUSIP No. 68620A104 13G Page 4 of 5 Pages 

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4. Ownership

     

    (a)Amount beneficially owned:

     

    1,404,620

     

    (b)Percent of class:

     

    20.86%

     

    (c)Number of shares as to which such person has:

     

    (i)  Sole power to vote or to direct the vote: 1,401,092

     

    (ii) Shared power to vote or to direct the vote: 3,528

     

    (iii) Sole power to dispose or to direct the disposition of: 1,404,620

     

    (iv) Shared power to dispose or to direct the disposition of: 0 

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

      

    Item 6.Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    CUSIP No. 68620A104 13G Page 5 of 5 Pages 

     

     Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

     

    Dated:    February 16, 2021

     

      ARK Investment Management LLC  
         
           
      By: /s/ Kellen Carter  
        Name:  Kellen Carter  
        Title:    Chief Compliance Officer  
           

     

     

     

    Get the next $ONVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of the FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA's push to phase out animal models, announced on April 10, is expected to provide a powerful accelerant to VivoSim's market adoption, disrupting a >$10B animal testing market with models that are more predictive and ethically sound. As FDA Commiss

      4/24/25 8:05:11 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • VivoSim to Carry Forward Organovo 3D Bioprinting

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (the "Company") announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc. A name change of the Company to VivoSim Labs, Inc. will be effective on April 24, 2025, and the Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "VIVS" at market open on April 24, 2025. No action is required by existing stockholders with respect to the name and ticker symbol change. The Company's common stock will continue to be listed on the Nasdaq Capital Market and the CUSIP number assigned to the Company's common stock (68620A302) wil

      4/23/25 8:05:21 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

      SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025. The Company expects to release full fiscal second-quarter financial results the week of June 9-13, 2025. The Company also gave guidance that, as its common stock has been trading above the $1.00 minimum bid price required, it expects to meet the requirements for continued listing on the Nasdaq Capita

      4/2/25 8:05:00 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Organovo Holdings Inc.

      SC 13G - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      11/14/24 3:34:49 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

      SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      2/12/24 6:17:19 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

      SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      2/5/24 6:08:57 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    SEC Filings

    See more
    • Organovo Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - VivoSim Labs, INC. (0001497253) (Filer)

      4/24/25 8:30:13 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organovo Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)

      4/23/25 8:06:08 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Organovo Holdings Inc.

      424B5 - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)

      4/11/25 9:16:35 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Staskey Norm

      3 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      1/8/25 4:05:03 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gobel David was granted 19,607 shares, increasing direct ownership by 100% to 39,214 units (SEC Form 4)

      4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      8/9/24 4:01:07 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Milhous Alison Tjosvold was granted 19,607 shares, increasing direct ownership by 50% to 58,821 units (SEC Form 4)

      4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      8/9/24 4:01:05 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

      SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer. Mr. Staskey has worked for Danforth Advisors since 2021, working as Chief Financial Officer for clients such as Azitra, Inc., a biotechnology company developing novel dermatology therapeutic technologies. Norm has over 25 years working in capital market and M&A transactions most recently as a Managing Director in EY's (formally Ernst & Young) national transactions practice wh

      1/6/25 8:05:55 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care